Since the evidence of ACE2 expression in tumors is mixed, with some studies showing increased expression, while others showing decreased expression, it is easy to speculate that low expression may act as a COVID-19 protective mechanism for cancer patients (Siljee et al., 2020; Winkler, 2020). Here, ACE2 is linked to cancer.